SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

HRMY

Harmony Biosciences
BEARISH
Impact 5/10
Horizonweeks Processed12d 14h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss is significant but partly driven by one-time milestone charges. Watch for the AET ANDA litigation ruling expected around February 2027, which could impact WAKIX exclusivity. The BP-205 Phase 1b data in Q1 2027 is a key pipeline catalyst.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$34.42
T+0 close · Nov 4, 2026 · via day close
Latest settled
−0.57%
T+5 · $34.22
Vs SPY
+0.35%
α at T+5
Next horizon
T+20
in 16d
  1. T+0 · Nov 4 $34.42entry
  2. T+1 · 12d ago −5.65%α −1.24% · $32.47
  3. T+5 · 6d ago −0.57%α +0.35% · $34.22
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Harmony Biosciences reported Q3 2026 WAKIX net revenue of $268.9M (+12% YoY), slightly below the $272.1M consensus. GAAP diluted EPS of $0.81 missed the $1.47 consensus, driven by a $25M milestone charge and higher royalties. The company reiterated full-year revenue guidance of $1.0B-$1.04B and highlighted positive early BP-205 MAD study data.

Key Financial Metrics

EPS
$0.81
est $1.47 · -44.9%
Revenue
$268.9M
est $272.1M · -1.2% · +12.3% YoY
Rating
miss
Guidance
$1.0B-$1.04B
maintained
Gross Margin
70%

Key Facts

  • Q3 2026 WAKIX net revenue $268.9M, +12% YoY from $239.5M, vs consensus $272.1M
  • GAAP diluted EPS $0.81, down from $0.87 YoY, vs consensus $1.47
  • Net income $48.2M vs $50.9M YoY; operating income $54.2M vs $65.5M YoY
  • Cost of product sold rose to 30% of revenue from 25% YoY, driven by new Novitium royalties
  • R&D expense $71.7M included a $25M milestone charge for MSN license
  • Cash and investments $1.05B as of Sept 30, 2026, up from $882.5M at Dec 31, 2025
  • Reiterated full-year WAKIX net revenue guidance of $1.0B-$1.04B
  • BP-205 MAD study showed favorable safety/tolerability; Phase 1b data expected Q1 2027
  • Pitolisant GR NDA under FDA review, PDUFA date April 1, 2027
  • CEO transition: Peter Anastasiou to succeed Jeffrey Dayno effective Jan 1, 2027

Financial Impact

EPS miss of ~45% vs consensus; revenue ~1.2% below consensus; operating income declined 17% YoY

revenueepsoperating incomegross margin

Risk Factors

  • AET ANDA litigation ruling expected Feb 2027 could threaten WAKIX exclusivity beyond March 2030
  • Gross margin compression from new royalty obligations may persist
  • CEO transition introduces execution risk despite planned continuity
  • Pipeline milestones (BP-205, pitolisant GR, EPX-100) are years from commercialization

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
72% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395197

Track record

20 reports on HRMY

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +14.82% at T+20 after the Jul 16, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $33.21 Now $32.96 −0.75% settles Dec 15
  2. Nov 4, 202612d ago 8-K Bearish 5/10 No price data
  3. Nov 4, 202612d ago Press Release Bearish 5/10 Viewing Entry $34.42 Now $32.96 +4.23% settles Dec 3
  4. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.02 Now $32.96 −10.97% settles Dec 2
  5. Oct 30, 202617d ago 8-K/A Neutral 3/10 Entry $37.91 Now $32.96 −13.06% settles Dec 1
  6. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $38.50 Now $32.96 −14.39% settles Nov 25
  7. Oct 13, 20264w ago 8-K Neutral 3/10 Entry $37.03 to $33.55 Now $32.96 −10.99% ▼ −9.40% −5.79% vs SPY
  8. Oct 1, 20266w ago Press Release Neutral 3/10 Entry $39.57 to $38.59 Now $32.96 −16.70% ▼ −2.48% −3.18% vs SPY
  9. Aug 4, 202614w ago 8-K Bullish 7/10 No price data
  10. Aug 4, 202614w ago Press Release Bullish 6/10 Entry $38.78 Now $32.96 −15.01% No price data
Showing 10 of 20

US Market Status

Market Closed · Opens Wed (11h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026